Author: Katie Cammarata

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high risk of the disease have been enrolled. The trial, led by Washington University School of Medicine in St. Louis, aims to determine whether stopping the early molecular changes that lead to symptomatic Alzheimer’s disease can prevent the […]

Individuals with sickle cell disease – a chronic illness where misshapen, sticky blood cells clump together, reducing oxygen delivery to organs – are at a higher risk for stroke and resulting cognitive disability. But even in the absence of stroke, many such patients struggle with remembering, focusing, learning and problem solving, among other cognitive problems, […]

For decades, the general consensus among neurologists and neuroscientists has been that ALS treatments would only be able to slow down or stop further progression of the disease. Function that had already been lost would probably not be recovered. But now, evidence is emerging that not only is functional improvement possible, it’s happening for some people […]

As a leading researcher of rare diseases that affect children’s brains, Jonathan D. Cooper, PhD, thought little about the gastrointestinal (GI) system. That is, until the parents of children with a condition that Cooper studies urged him to investigate why debilitating digestive issues troubled their kids, who suffer from an incurable and fatal neurodegenerative brain condition […]

The gas xenon, like the other noble, or inert, gases, is known for doing very little. The class of elements, because of its molecular structure, don’t typically interact with many chemicals.  But a new mouse study shows one possible use case for xenon — as a treatment for Alzheimer’s disease. The paper, published Wednesday in Science Translational […]